Peptide News Digest

#Innogen

1 story

Industry · View digest

Innogen Licenses Its GLP-1 Drug Efsubaglutide Alfa to Abu Dhabi's Arcera in a Deal Worth More Than $1 Billion

Innogen Pharmaceuticals granted Arcera Life Sciences exclusive rights to sell efsubaglutide alfa, a long-acting GLP-1 fusion protein approved in China for blood sugar control in adults with type 2 diabetes, in selected countries in Africa, Eastern Europe, Latin America, and the Middle East, the companies announced on November 19, Pharmaceutical Executive reported. Innogen gets $38 million in upfront and near-term payments, including $15 million upfront, plus sales milestones and tiered royalties of up to double-digit percentages, for a total potential value above $1 billion. Arcera will handle regulatory filings and sales, and the drug is not approved for obesity.